Dr Kenderian on the Efficacy of Liso-Cel in R/R CLL/SLL
Saad J. Kenderian, MB, CHB, consultant, discusses the safety and efficacy findings derived from the phase 1/2 TRANSCEND CLL 004 study in CLL/SLL.
Source: onclive.com
Stay updated with breaking news from Saadj Kenderian. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Saad J. Kenderian, MB, CHB, consultant, discusses the safety and efficacy findings derived from the phase 1/2 TRANSCEND CLL 004 study in CLL/SLL.
Saad J. Kenderian, MB, CHB, discusses ongoing research taking place to potentially move liso-cel into earlier lines of therapy for patients with CLL.